Literature DB >> 9000144

Glucose-regulated stresses cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma protein in human cancer cells.

A Tomida1, H Suzuki, H D Kim, T Tsuruo.   

Abstract

Glucose-regulated stress response of cancer cells occurs during the growth of solid tumors and is induced in culture by treatments with various agents, including 2-deoxyglucose, glucosamine, and calcium ionophore A23187. We previously reported that the three stressors commonly induced cell-cycle arrest in the G1 phase and resistance to antitumor drugs in human cancer A2780 and HT-29 cells. In this study, we investigated the mechanisms of stress-induced G1 arrest by determining the expression of cell-cycle-regulating proteins. Among G1 cyclins and cyclin-dependent kinases (cdk) examined, the expression levels of cyclin D1 preferentially decreased in the stressed cells. A time-course study showed that the decrease in cyclin D1 coincided with the appearance of hypophosphorylated retinoblastoma protein (pRb), which is the growth suppressive form. These findings suggest that the stress-induced G1 arrest is mediated through the down-regulation of cyclin D1-associated kinases (cdk4/6), pRb kinases during G1 phase. This was also supported by decreased cdk4 expression in stressed HT-29 cells. In addition, p21WAF1, a cdk inhibitor, was induced in the stressed cells, particularly A23187-treated cells. A23187, compared with the other stressors, caused extreme pRb hypophosphorylation, suggesting that p21WAf1 is involved in the regulation of pRb phosphorylation in the stressed cells. Our present findings could explain a molecular-based mechanism of a growth-arrested quiescent state and also resistance to chemotherapy of solid tumor cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9000144

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Identification and characterization of molecular interactions between glucose-regulated proteins (GRPs) mortalin/GRP75/peptide-binding protein 74 (PBP74) and GRP94.

Authors:  S Takano; R Wadhwa; Y Mitsui; S C Kaul
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

2.  Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression.

Authors:  J W Brewer; L M Hendershot; C J Sherr; J A Diehl
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

3.  The RB-E2F1 pathway regulates autophagy.

Authors:  Hong Jiang; Vanesa Martin; Candelaria Gomez-Manzano; David G Johnson; Marta Alonso; Erin White; Jing Xu; Timothy J McDonnell; Naoki Shinojima; Juan Fueyo
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

4.  Reduced expression of members of the mhc-i antigen processing machinery in ethnic Uighur women with cervical cancer in the Xinjiang region of China.

Authors:  A Haimiti; Y Hailiman; A Gulina; J Du; Z Hao; X L Rong; A Zainuer; W Qin; S Lalai
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

5.  3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs.

Authors:  Linda Strandberg Ihrlund; Emma Hernlund; Omar Khan; Maria C Shoshan
Journal:  Mol Oncol       Date:  2008-01-13       Impact factor: 6.603

6.  Mechanism-based screen establishes signalling framework for DNA damage-associated G1 checkpoint response.

Authors:  Elizabeth Richardson; Simon R Stockwell; He Li; Wynne Aherne; Maria Emanuela Cuomo; Sibylle Mittnacht
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

7.  The novel IGF-IR/Akt-dependent anticancer activities of glucosamine.

Authors:  Ki-Hoon Song; Ju-Hee Kang; Jong-Kyu Woo; Jeong-Seok Nam; Hye-Young Min; Ho-Young Lee; Soo-Youl Kim; Seung-Hyun Oh
Journal:  BMC Cancer       Date:  2014-01-20       Impact factor: 4.430

8.  A novel mutant from apoptosis-resistant colon cancer HT-29 cells showing hyper-apoptotic response to hypoxia, low glucose and cisplatin.

Authors:  H Suzuki; A Tomida; T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1998-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.